PMID- 36097079
OWN - NLM
STAT- MEDLINE
DCOM- 20230224
LR  - 20230306
IS  - 1432-5241 (Electronic)
IS  - 0364-216X (Linking)
VI  - 47
IP  - 1
DP  - 2023 Feb
TI  - Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A 
      Network Meta-Analysis of Randomized Controlled Trials.
PG  - 365-377
LID - 10.1007/s00266-022-03018-y [doi]
AB  - BACKGROUND: Botulinum toxin type A (BoNT/A) has been used in aesthetic 
      applications worldwide, including glabellar lines. Currently, four BoNT/A 
      preparations were approved for the improvement of moderate-to-severe glabellar 
      lines: onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and 
      prabotulinumtoxinA. DaxibotulinumtoxinA is a new form of BoNT/A drug that is 
      developed in clinical application. We performed this network meta-analysis (NMA) 
      to assess the efficacy and safety of all these different BoNT/A formulations for 
      treating glabellar lines. METHODS: The investigators searched randomized 
      controlled trials (RCTs) using the Medical Subject Headings (MeSH) terms 
      "botulinum toxin" and "glabellar lines." We searched the relevant studies in 
      electronic databases as following: PubMed, Elsevier, EMBASE and the Cochrane 
      Library. The end points included the percentage of subjects with a glabellar line 
      severity (GLS) score of none (0) or mild (1), and the percentage of subjects 
      achieving >/= 1-point and 2-point improvement in glabellar line severity at maximum 
      frown at approximately month 1 by the investigators' assessment. RESULTS: All 
      formulations of BoNT/A were far superior to placebo in efficacy. 
      DaxibotulinumtoxinA was the only treatment that significantly increased the 
      proportion of subjects achieving >/= 1 point improvement in GLS score compared with 
      other BoNT/A formulations. Moreover, daxibotulinumtoxinA was ranked the highest 
      for the proportion of subjects achieving >/= 2-point improvement in GLS score. No 
      significant differences were revealed for the incidence of any adverse events 
      (AEs) that related to treatment or drug among all BoNT/A preparations. 
      CONCLUSION: The overall results of this NMA suggested that daxibotulinumtoxinA is 
      a new BoNT/A preparation that may be not only more effective but also 
      well-tolerated for the treatment of glabellar lines. LEVEL OF EVIDENCE I: This 
      journal requires that authors assign a level of evidence to each article. For a 
      full description of these Evidence-Based Medicine ratings, please refer to the 
      Table of Contents or the online Instructions to Authors www.springer.com/00266 .
CI  - (c) 2022. Springer Science+Business Media, LLC, part of Springer Nature and 
      International Society of Aesthetic Plastic Surgery.
FAU - Li, Xue
AU  - Li X
AUID- ORCID: 0000-0003-2583-6499
AD  - Department of Dermatology, Qingdao University Medical College Affiliated Yantai 
      Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, 
      Shandong province, China.
FAU - Sui, Changlin
AU  - Sui C
AD  - Department of Dermatology, Qingdao University Medical College Affiliated Yantai 
      Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, 
      Shandong province, China.
FAU - Xia, Xiujuan
AU  - Xia X
AD  - Department of Dermatology, Qingdao University Medical College Affiliated Yantai 
      Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, 
      Shandong province, China. snowli211@163.com.
FAU - Chen, Xianjin
AU  - Chen X
AD  - Department of Dermatology, Qingdao University Medical College Affiliated Yantai 
      Yuhuangding Hospital, No 20, Yuhuangding East Road, Zhifu district, Yantai, 
      Shandong province, China. chenxj1975@gmail.com.
LA  - eng
GR  - 202104120294/the Medical Health Science and Technology Project of Shandong 
      Provincial Health Commission/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220912
PL  - United States
TA  - Aesthetic Plast Surg
JT  - Aesthetic plastic surgery
JID - 7701756
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - 0 (Neuromuscular Agents)
SB  - IM
MH  - Humans
MH  - *Botulinum Toxins, Type A
MH  - *Neuromuscular Agents
MH  - Network Meta-Analysis
MH  - Forehead
MH  - *Skin Aging
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Double-Blind Method
OTO - NOTNLM
OT  - Botulinum toxin type A (BoNT/A)
OT  - Glabellar lines (GL)
OT  - Network meta-analysis (NMA)
EDAT- 2022/09/13 06:00
MHDA- 2023/02/25 06:00
CRDT- 2022/09/12 23:57
PHST- 2022/05/25 00:00 [received]
PHST- 2022/07/06 00:00 [accepted]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/09/12 23:57 [entrez]
AID - 10.1007/s00266-022-03018-y [pii]
AID - 10.1007/s00266-022-03018-y [doi]
PST - ppublish
SO  - Aesthetic Plast Surg. 2023 Feb;47(1):365-377. doi: 10.1007/s00266-022-03018-y. 
      Epub 2022 Sep 12.